Cellular immunotherapy as a beacon of hope for hematological malignancies.
Blood Research.2015;50(3):126-128. doi:10.5045/br.2015.50.3.126
Blood Research
1969 to Present ISSN: 2287-979X
Year of publication
Sort by
DISPLAY OPTIONS
Format:
Per page:
Biomarkers for hepatic sinusoidal obstruction syndrome after hematopoietic cell transplantation.
Blood Research.2015;50(3):123-125. doi:10.5045/br.2015.50.3.123
No abstract available.
Biological Markers* ; Cell Transplantation* ; Hepatic Veno-Occlusive Disease* ; Transplants* ; Biomarkers
Biological Markers* ; Cell Transplantation* ; Hepatic Veno-Occlusive Disease* ; Transplants* ; Biomarkers
Lymphoplasmacytic non-Hodgkin lymphoma/Waldenstrom's macroglobulinemia with CD5+, CD23+, and CD10-.
Blood Research.2013;48(4):300-303. doi:10.5045/br.2013.48.4.300
No abstract available.
Waldenstrom Macroglobulinemia*
Waldenstrom Macroglobulinemia*
Acute promyelocytic leukemia with an unusual presentation of secondary postpartum hemorrhage.
Blood Research.2013;48(4):299-300. doi:10.5045/br.2013.48.4.299
No abstract available.
Leukemia, Promyelocytic, Acute* ; Postpartum Hemorrhage* ; Postpartum Period*
Leukemia, Promyelocytic, Acute* ; Postpartum Hemorrhage* ; Postpartum Period*
Late but effective long-term response to splenectomy in the treatment of immune thrombocytopenia.
Blood Research.2013;48(4):297-298. doi:10.5045/br.2013.48.4.297
Blood Research.2013;48(4):296-297. doi:10.5045/br.2013.48.4.296
No abstract available.
Aged* ; B-Lymphocytes* ; Bone Marrow* ; Cyclophosphamide* ; Doxorubicin* ; Humans ; Lymphoma, B-Cell* ; Prednisone* ; Vincristine* ; Rituximab
Aged* ; B-Lymphocytes* ; Bone Marrow* ; Cyclophosphamide* ; Doxorubicin* ; Humans ; Lymphoma, B-Cell* ; Prednisone* ; Vincristine* ; Rituximab
Successful treatment of steroid resistant hypereosinophilic syndrome with low-dose CsA.
Blood Research.2013;48(4):293-295. doi:10.5045/br.2013.48.4.293
No abstract available.
Hypereosinophilic Syndrome*
Hypereosinophilic Syndrome*
Blood Research.2013;48(4):292-293. doi:10.5045/br.2013.48.4.292
Nodular lymphoid hyperplasia of the stomach in a patient with multiple submucosal tumors.
Blood Research.2013;48(4):287-291. doi:10.5045/br.2013.48.4.287
Nodular lymphoid hyperplasia of the stomach is a rare lymphoproliferative disorder. Here, we report a 38-year-old man who presented with multiple submucosal tumors of the stomach. Histologically, the lesions were characterized by multiple discrete submucosal nodules of lymphoid cells. The infiltrates between the lymphoid follicles were composed mainly of medium-sized lymphoid cells with abundant clear cytoplasm, as well as a few large cells with vesicular nuclei. The gastric mucosa exhibited multifocal lymphoid aggregates and some of the epithelial cells were infiltrated by small lymphocytes mimicking lymphoepithelial lesions. Histopathology was consistent with mucosa-associated lymphoid tissue lymphoma. However, the infiltrating lymphoid cells were positive for CD2, CD3, CD5, and CD7. In addition, polymerase chain reaction analysis of the immunoglobulin heavy chain and T-cell receptor gene rearrangements demonstrated polyclonality. This case was diagnosed as reactive lymphoid hyperplasia of the stomach.
Adult ; Cytoplasm ; Epithelial Cells ; Gastric Mucosa ; Genes, T-Cell Receptor ; Humans ; Hyperplasia* ; Immunoglobulin Heavy Chains ; Lymphocytes ; Lymphoma, B-Cell, Marginal Zone ; Lymphoproliferative Disorders ; Polymerase Chain Reaction ; Pseudolymphoma ; Stomach*
Adult ; Cytoplasm ; Epithelial Cells ; Gastric Mucosa ; Genes, T-Cell Receptor ; Humans ; Hyperplasia* ; Immunoglobulin Heavy Chains ; Lymphocytes ; Lymphoma, B-Cell, Marginal Zone ; Lymphoproliferative Disorders ; Polymerase Chain Reaction ; Pseudolymphoma ; Stomach*
Blood Research.2013;48(4):282-286. doi:10.5045/br.2013.48.4.282
BACKGROUND: Currently, the greatest challenge in hemophilia treatment is managing hemophilia patients with inhibitors. The two main bypassing agents that are used to treat hemophilia patients with inhibitors are activated prothrombin complex concentrates (APCC) and recombinant factor VIIa (rFVIIa). Hemophilia patients with inhibitors can develop bleeding episodes, that are refractory to monotherapy with either APCC or rFVIIa and thus are often difficult to manage. METHODS: This report describes a retrospective chart review of four hospitalized patients with severe hemophilia and inhibitors who were treated with sequential therapy of APCC and rFVIIa for refractory bleeding. Sequential therapy was defined as the administration of both rFVIIa and APCC within 12 h. RESULTS: In 5 episodes experienced by 4 patients with inhibitors, bleeding was not controlled by single bypass treatment, but it was controlled when two agents were sequentially administered. Sequential therapy was administered by alternating one APCC dose to 1 to 2 rFVIIa doses, with dosing intervals ranging from 3 to 6 h. All bleeding episodes were controlled within 12 to 24 h. Sequential therapy was discontinued after 2 to 5 days. No adverse clinical events, such as thrombosis, were observed. CONCLUSION: Sequential therapy with APCC and rFVIIa was efficacious without adverse events; however, attention on thrombosis is needed. In addition, a prospective clinical trial is needed to provide further evidence for this treatment.
Factor VIIa* ; Hemophilia A* ; Hemorrhage* ; Humans ; Prothrombin* ; Retrospective Studies ; Thrombosis
Factor VIIa* ; Hemophilia A* ; Hemorrhage* ; Humans ; Prothrombin* ; Retrospective Studies ; Thrombosis
Country
Republic of Korea
Publisher
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
ElectronicLinks
http://synapse.koreamed.org/LinkX.php?code=3072BREditor-in-chief
Seog-Woon Kwon
journal@bloodresearch.or.kr
Abbreviation
Blood Res
Vernacular Journal Title
ISSN
2287-979X
EISSN
2288-0011
Year Approved
2007
Current Indexing Status
Currently Indexed
Start Year
1969
Description
Blood Research is a peer-reviewed open-access journal and delivers important clinical, translational and basic research results in hematology to the readers worldwide. The research areas covered by Blood Research include hematopoiesis, stem cell biology, stem cell transplantation, thrombosis, hemostasis, hematologic malignancy, pediatric hematology, laboratory hematology, immunohematology, transfusion medicine, immunology, and other hematology-related fields. Blood Research publishes Original Articles, Review Articles, Editorials, Perspectives, Letters to the Editor, and Images of Hematology. It is published online (http://bloodresearch.or.kr) and in print quarterly (March 31, June 30, September 30, and December 31). Any physicians or researchers throughout the world can submit a manuscript written in English.
Previous Title
Powered by IMICAMS(
备案号: 11010502037788, 京ICP备10218182号-8)